Flow Cytometry and Effusions in Lymphoproliferative Processes and Other Hematologic Neoplasias

Beata Bode-Lesniewska1

  • 1Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.

Acta Cytologica
|September 1, 2016
PubMed

Insights

Diagnosing indolent lymphoma in lymphocyte-rich effusions is challenging. Flow cytometry (FC) aids cytopathologists by integrating microscopy, immunophenotyping, and molecular findings for accurate hematologic neoplasia diagnosis.

Area of Science:

  • Hematopathology
  • Cytopathology
  • Immunology

Background:

  • Distinguishing reactive lymphocytosis from indolent lymphoma in effusions is difficult using microscopy alone.
  • Flow cytometry (FC) is a valuable tool for analyzing body cavity fluids.
  • FC aids in diagnosing new lymphomas and managing known hematologic malignancies.

Purpose of the Study:

  • To review recent studies on flow cytometry applications in body cavity effusions for hematologic neoplasia.
  • To emphasize an integrative diagnostic approach combining microscopy, immunophenotyping, and molecular data.
  • To provide cytopathologists with advanced diagnostic perspectives aligned with WHO classifications.

Main Methods:

  • Review of published literature on flow cytometry in effusion analysis.
  • Integration of microscopical, immunophenotypical, and molecular findings.
  • Interpretation of results within the framework of the WHO classification of hematolymphoid malignancies.

Main Results:

  • Flow cytometry significantly enhances the diagnostic accuracy of lymphocyte-rich effusions.
  • An integrative approach improves the differentiation between reactive and neoplastic processes.
  • FC provides crucial data for diagnosing indolent lymphomas and other hematologic malignancies.

Conclusions:

  • Flow cytometry is indispensable for advanced diagnostics in body cavity effusions.
  • Integrating FC with other methods offers new perspectives for cytopathologists.
  • This approach supports accurate classification and management of hematologic neoplasia.